India, Sept. 16 -- The proposed changes to US tariffs on generic medicines have put Indian pharmaceutical companies under the spotlight. The move could affect companies based on their exposure to the US market, manufacturing footprint and ability to manage higher costs.

Considering that Indian manufacturers play a critical role in providing medications to the United States, it is of particular interest for the investors to see how corporations will react to the newly imposed tariff system, as the disparity in contribution to the US income and local production may be significant for different stocks.

What Trump's New Pharma Tariffs Mean for Indian Drugmakers? On July 21, 2026, US President Donald Trump announced a phased tariff plan fo...